Company shines on world stage


Sienna Cancer Diagnostics chief executive Matthew Hoskin in the laboratory. Picture: ANDREW BATSCH

A SCORESBY company has developed a test that can help urologists detect bladder cancer earlier.

Sienna Cancer Diagnostics is a medical technology company that develops and commercialises cancerrelated in-vitro diagnostic tests for the pathology laboratory market.

The first product developed and brought to market by Sienna is the first ever in-vitro diagnostic test for the detection of hTERT, a biomarker that is a component of telomerase and plays a role in cancer proliferation.

Chief executive Matthew Hoskin said testing for the presence of the biomarker hTERT provided information to diagnosing physicians to help them manage the patients they are investigating or monitoring for bladder cancer.

“Doing that test alongside the standard non-invasive test for bladder cancer, provides clinical data that the physician can use to help determine whether that patient needs to go on and have a further diagnostic procedure which is a more painful and expensive procedure,” Mr Hoskin said.

Sienna listed on the Australian Securities Exchange in 2017, and has hit a number of milestones including its first sale in Switzerland.